A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers

Inclusion Criteria: * Male or female healthy volunteers * Body mass index (BMI) of 18-32 kg/m2 * Female subjects must have a negative serum pregnancy test result prior to entry into the study * All female subjects must not be of child-bearing potential * All male subjects with female partners of childbearing potential must consent to use a medically acceptable double-barrier method of contraception and not donate sperm throughout the study period and for at least 3 months (90 days) after the last dose of study medication * The subject agrees to abstain from grapefruit or grapefruit juice for at least 2 weeks prior to the first dose and until completion of the pharmacokinetic sampling (Day 15) * The subject must be able to provide written informed consent Exclusion Criteria: * Any acute or chronic disease state, including but not limited to cardiovascular, dermatological, endocrine, gastrointestinal, hepatic, pulmonary, and renal conditions determined to be clinically significant by the Investigator * Any clinically significant abnormal clinical laboratory tests as determined by the Investigator * Any concomitant medications (including prescription, over-the-counter or illicit) within either 30 days or five half-lives (whichever is shorter) prior to dosing * Positive urine drug screen for any illicit drugs * Use of tobacco or any nicotine-containing products during the previous three months * Grapefruit juice within two weeks prior to first dose * Participation in a clinical investigation of any drug, biological or other investigational therapy within 30 days prior to dosing * Signs and/or symptoms such as orthostatic hypotension, fatigue, anorexia, nausea, abdominal pain, joint and muscle pain if considered to be a marker of adrenal insufficiency * History of an allergic reaction to mifepristone or fluvastatin * Positive serum test for human immunodeficiency virus (HIV), hepatitis B virus or hepatitis C virus * Blood donation within 30 days of dosing